INmune Bio (INMB) Fundamentals 2026 — Revenue Analysis | SniperIQ

.85 on the NASDAQ. This SniperIQ fundamentals page covers INmune Bio's valuation, profitability (net margin 0.0%), revenue ($50,000 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is INmune Bio's market cap?

INmune Bio (INMB) has a market capitalization of approximately $49M, trading at

.85 on the NASDAQ. Market cap moves with the live share price.

What is INmune Bio's P/E ratio?

INmune Bio's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is INmune Bio?

INmune Bio runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does INmune Bio generate?

INmune Bio reported revenue of $50,000 for fiscal year 2025, with net income of -$46M and earnings per share (EPS) of -1.86. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does INmune Bio pay a dividend?

INmune Bio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is INmune Bio financially healthy?

INmune Bio carries a debt-to-equity ratio of 0.08x and a current ratio of 4.24x, with a market beta of 0.98. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is INmune Bio a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For INmune Bio (INMB) the key facts are: market cap $49M, revenue $50,000, 52-week range 1.09-3.244. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.